Sanofi Ebitda from 2010 to 2024

SNY Stock  USD 48.28  0.30  0.63%   
Sanofi ADR EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about 11.3 B in 2024. During the period from 2010 to 2024, Sanofi ADR EBITDA regression line of annual values had r-squared of  0.23 and arithmetic mean of  11,753,660,512. View All Fundamentals
 
EBITDA  
First Reported
2002-06-30
Previous Quarter
B
Current Value
4.2 B
Quarterly Volatility
3.9 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sanofi ADR financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanofi ADR's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.3 B, Interest Expense of 607 M or Selling General Administrative of 11.2 B, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0232 or PTB Ratio of 1.44. Sanofi financial statements analysis is a perfect complement when working with Sanofi ADR Valuation or Volatility modules.
  
Check out the analysis of Sanofi ADR Correlation against competitors.
For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

Latest Sanofi ADR's Ebitda Growth Pattern

Below is the plot of the Ebitda of Sanofi ADR over the last few years. It is Sanofi ADR's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sanofi ADR's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Sanofi Ebitda Regression Statistics

Arithmetic Mean11,753,660,512
Geometric Mean10,589,663,872
Coefficient Of Variation30.03
Mean Deviation2,034,404,924
Median11,564,000,000
Standard Deviation3,529,790,211
Sample Variance12459418.9T
Range16.7B
R-Value0.48
Mean Square Error10361851T
R-Squared0.23
Significance0.07
Slope376,676,263
Total Sum of Squares174431865.1T

Sanofi Ebitda History

202411.3 B
202312.6 B
202214.3 B
202111.5 B
202017.9 B
201915.1 B
201811.2 B

About Sanofi ADR Financial Statements

Sanofi ADR investors use historical fundamental indicators, such as Sanofi ADR's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sanofi ADR. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA12.6 B11.3 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.